Oramed Pharmaceuticals (ORMP) Short Interest Ratio & Short Volume $2.26 -0.04 (-1.74%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Oramed Pharmaceuticals Short Interest DataOramed Pharmaceuticals (ORMP) has a short interest of 300,000 shares. This marks a 0.50% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.0, indicating that it would take 3.0 days of the average trading volume of 107,531 shares to cover all short positions.Current Short Interest300,000 sharesPrevious Short Interest298,500 sharesChange Vs. Previous Month+0.50%Dollar Volume Sold Short$714,000.00Short Interest Ratio3.0 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares40,310,000 sharesPercentage of Shares Shorted0.74%Today's Trading Volume60,933 sharesAverage Trading Volume107,531 sharesToday's Volume Vs. Average57% Short Selling Oramed Pharmaceuticals? Sign up to receive the latest short interest report for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartORMP Short Interest Over TimeORMP Days to Cover Over TimeORMP Percentage of Float Shorted Over Time Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Oramed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/2024300,000 shares $714,000.00 +0.5%N/A3 $2.38 10/15/2024298,500 shares $701,475.00 -12.3%N/A3 $2.35 9/30/2024340,400 shares $830,576.00 -4.0%N/A3.4 $2.44 9/15/2024354,400 shares $882,456.00 -2.4%N/A2.9 $2.49 8/31/2024363,200 shares $868,048.00 +53.0%N/A2.7 $2.39 8/15/2024237,400 shares $557,890.00 -14.6%N/A1.7 $2.35 Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/2024278,100 shares $709,155.00 -16.9%N/A2.1 $2.55 7/15/2024334,700 shares $846,791.00 -36.7%N/A2.7 $2.53 6/30/2024529,100 shares $1.36 million +13.1%N/A4 $2.57 6/15/2024467,800 shares $1.05 million +63.3%N/A4 $2.25 5/31/2024286,500 shares $624,570.00 -5.9%N/A2.6 $2.18 5/15/2024304,600 shares $727,994.00 -6.2%N/A2.5 $2.39 4/30/2024324,600 shares $753,072.00 -11.7%N/A2.2 $2.32 4/15/2024367,600 shares $889,592.00 -37.0%N/A2.2 $2.42 3/31/2024583,900 shares $1.70 million +20.6%N/A3.3 $2.92 3/15/2024484,000 shares $1.41 million -3.3%N/A2.6 $2.92 2/29/2024500,700 shares $1.65 million -27.6%N/A2.5 $3.29 2/15/2024691,600 shares $2.17 million +76.0%N/A3.6 $3.14 1/31/2024393,000 shares $1.18 million +5.3%N/A2.1 $3.00 1/15/2024373,200 shares $873,288.00 +17.4%N/A1.8 $2.34 12/31/2023318,000 shares $734,580.00 -15.4%N/A1.6 $2.31 12/15/2023376,000 shares $827,200.00 -10.0%N/A2 $2.20 11/30/2023417,800 shares $927,516.00 -10.3%N/A2.4 $2.22 11/15/2023465,900 shares $959,754.00 +3.6%N/A2.6 $2.06 10/31/2023449,800 shares $823,134.00 -23.6%N/A2.5 $1.83 10/15/2023588,400 shares $1.28 million -2.2%N/A3.5 $2.18 9/30/2023601,800 shares $1.57 million +6.3%N/A3.4 $2.61 9/15/2023566,200 shares $1.72 million +25.8%N/A2.8 $3.04 8/31/2023450,000 shares $1.48 million -13.7%N/A1.8 $3.28 8/15/2023521,600 shares $1.63 million +4.0%N/A1.4 $3.13 7/31/2023501,400 shares $1.70 million -25.9%N/A0.6 $3.39 7/15/2023677,000 shares $2.17 million -15.1%N/A0.8 $3.21 6/30/2023797,800 shares $2.86 million -6.5%N/A0.9 $3.58 6/15/2023852,900 shares $3.45 million -7.6%N/A0.9 $4.04 5/31/2023923,300 shares $3.73 million +89.9%N/A1 $4.04 5/15/2023486,300 shares $1.52 million -6.6%N/A0.5 $3.13 4/30/2023520,400 shares $1.18 million -33.4%N/A0.7 $2.27 4/15/2023781,200 shares $1.75 million -1.0%N/A0.9 $2.24 3/31/2023789,300 shares $1.72 million -19.9%N/A0.5 $2.18 3/15/2023985,700 shares $1.99 million -7.0%N/A0.6 $2.02This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here 2/28/20231,060,000 shares $2.23 million +8.3%N/A0.6 $2.10 2/15/2023978,500 shares $2.15 million +3.4%N/A0.6 $2.20 1/31/2023946,000 shares $1.88 million -65.6%N/A0.6 $1.99 1/15/20232,750,000 shares $6.19 million -2.5%N/A2.1 $2.25 12/30/20222,820,000 shares $33.92 million +4.8%N/A6.9 $12.03 12/15/20222,690,000 shares $22.00 million -2.2%N/A9.1 $8.18 11/30/20222,750,000 shares $23.24 million -5.5%N/A10.5 $8.45 11/15/20222,910,000 shares $26.19 million -3.6%N/A10.9 $9.00 10/31/20223,020,000 shares $21.47 million +0.7%N/A11 $7.11 10/15/20223,000,000 shares $18.72 million -3.2%N/A9.4 $6.24 9/30/20223,100,000 shares $20.09 million +4.7%N/A3.7 $6.48 9/15/20222,960,000 shares $24.92 million -0.3%N/A2.3 $8.42 8/31/20222,970,000 shares $25.42 million -0.7%N/A2.2 $8.56 8/15/20222,990,000 shares $29.63 million -6.9%N/A2.1 $9.91 7/31/20223,210,000 shares $28.18 million -10.6%N/A2.1 $8.78 7/15/20223,590,000 shares $28.65 million +30.1%N/A2.3 $7.98 6/30/20222,760,000 shares $12.64 million -25.4%N/A1.8 $4.58 6/15/20223,700,000 shares $14.65 million +12.8%30.1%4.7 $3.96 5/31/20223,280,000 shares $15.19 million +1.6%N/A5.1 $4.63 5/15/20223,230,000 shares $14.76 million +26.2%N/A5.3 $4.57 4/30/20222,560,000 shares $13.16 million +15.8%N/A4.8 $5.14 4/15/20222,210,000 shares $15.16 million -6.8%N/A3.6 $6.86 3/31/20222,370,000 shares $20.50 million +4.9%N/A3.8 $8.65 3/15/20222,260,000 shares $20.05 million +2.7%N/A3.1 $8.87 2/28/20222,200,000 shares $22.66 million -2.2%N/A2.8 $10.30 2/15/20222,250,000 shares $26.15 million +2.3%N/A2.5 $11.62 1/31/20222,200,000 shares $19.71 million +9.5%N/A2.3 $8.96 1/15/20222,010,000 shares $22.21 million -9.1%N/A2.2 $11.05 12/31/20212,210,000 shares $31.56 million +10.0%N/A2.6 $14.28 12/15/20212,010,000 shares $30.33 million +122.9%N/A2.5 $15.09 11/30/2021901,600 shares $17.33 million -3.4%N/A1.1 $19.22 11/15/2021933,400 shares $26.28 million -3.5%N/A1.2 $28.16 10/29/2021967,400 shares $22.65 million -7.9%N/A1.2 $23.41 10/15/20211,050,000 shares $23.16 million -3.7%3.7%1.3 $22.06 9/30/20211,090,000 shares $23.96 million -2.7%3.8%1.2 $21.98 9/15/20211,120,000 shares $21.78 million -5.9%3.9%1.3 $19.45 8/31/20211,190,000 shares $23.42 million -13.8%4.2%1.5 $19.68 8/13/20211,380,000 shares $24.40 million -27.8%4.9%1.8 $17.68 7/30/20211,910,000 shares $27.10 million -14.7%6.9%2.8 $14.19 7/15/20212,240,000 shares $28.45 million -6.3%8.1%4.1 $12.70 6/30/20212,390,000 shares $31.98 million +10.7%8.9%4.7 $13.38 6/15/20212,160,000 shares $28.84 million -12.9%8.0%4.7 $13.35 5/28/20212,480,000 shares $28.57 million -0.8%9.6%3.8 $11.52 5/14/20212,500,000 shares $25.65 million +7.3%9.7%4 $10.26 4/30/20212,330,000 shares $25.33 million +4.5%9.1%3.4 $10.87 4/15/20212,230,000 shares $20.69 million +0.5%8.7%2.6 $9.28 3/31/20212,220,000 shares $22.44 million +22.7%9.0%2.7 $10.11 3/15/20211,810,000 shares $17.01 million +4.0%7.4%2.2 $9.40 2/26/20211,740,000 shares $15.57 million -4.4%7.1%2.6 $8.95 2/12/20211,820,000 shares $18.56 million +45.6%7.6%2 $10.20This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here 1/29/20211,250,000 shares $8.74 million +54.8%5.3%1.5 $7.00 1/15/2021807,700 shares $3.60 million No Change3.8%1.3 $4.46 1/31/2020442,300 shares $2.31 million -1.4%3.3%2 $5.23 1/15/2020442,300 shares $2.34 million -1.4%3.3%2 $5.28 12/31/2019448,700 shares $2.35 million -23.5%3.3%2.1 $5.23 ORMP Short Interest - Frequently Asked Questions What is Oramed Pharmaceuticals' current short interest? Short interest is the volume of Oramed Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 300,000 shares of ORMP short. Learn More on Oramed Pharmaceuticals' current short interest. What is a good short interest ratio for Oramed Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORMP shares currently have a short interest ratio of 3.0. Learn More on Oramed Pharmaceuticals's short interest ratio. Is Oramed Pharmaceuticals' short interest increasing or decreasing? Oramed Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totaling 300,000 shares, an increase of 0.5% from the previous total of 298,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oramed Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oramed Pharmaceuticals: Valneva SE (0.06%), Amylyx Pharmaceuticals, Inc. (3.13%), Ginkgo Bioworks Holdings, Inc. (20.69%), Alector, Inc. (6.24%), Q32 Bio Inc. (15.96%), Contineum Therapeutics, Inc. (7.90%), Cryoport, Inc. (6.10%), Kamada Ltd. (0.09%), Alpha Teknova, Inc. (2.71%), biote Corp. (2.70%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Oramed Pharmaceuticals stock? Short selling ORMP is an investing strategy that aims to generate trading profit from Oramed Pharmaceuticals as its price is falling. ORMP shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oramed Pharmaceuticals? A short squeeze for Oramed Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ORMP, which in turn drives the price of the stock up even further. How often is Oramed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORMP, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Valneva Short Interest Data Amylyx Pharmaceuticals Short Interest Data Ginkgo Bioworks Short Interest Data Alector Short Interest Data Q32 Bio Short Interest Data Contineum Therapeutics Short Interest Data Cryoport Short Interest Data Kamada Short Interest Data Alpha Teknova Short Interest Data biote Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORMP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORMP Stock Alerts